Literature DB >> 20535554

Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells.

Gail D Zeevalk1, Laura P Bernard, F T Guilford.   

Abstract

A liposomal preparation of glutathione (GSH) was investigated for its ability to replenish intracellular GSH and provide neuroprotection in an in vitro model of Parkinson's disease using paraquat plus maneb (PQMB) in rat mesencephalic cultures. In mixed neuronal/glial cultures depleted of intracellular GSH, repletion to control levels occurred over 4 h with liposomal-GSH or non-liposomal-GSH however, liposomal-GSH was 100-fold more potent; EC(50s) 4.75 μM and 533 μM for liposomal and non-liposomal-GSH, respectively. Liposomal-GSH utilization was also observed in neuronal cultures, but with a higher EC(50) (76.5 μM), suggesting that glia facilitate utilization. Blocking γ-glutamylcysteine synthetase with buthionine sulfoxamine prevented replenishment with liposomal-GSH demonstrating the requirement for catabolism and resynthesis. Repletion was significantly attenuated with endosomal inhibition implicating the endosomal system in utilization. Liposomal-GSH provided dose-dependent protection against PQMB with an EC(50) similar to that found for repletion. PQMB depleted intracellular GSH by 50%. Liposomal-GSH spared endogenous GSH during PQMB exposure, but did not require GSH biosynthesis for protection. No toxicity was observed with the liposomal preparation at 200-fold the EC(50) for repletion. These findings indicate that glutathione supplied in a liposomal formulation holds promise as a potential therapeutic for neuronal maintenance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535554     DOI: 10.1007/s11064-010-0217-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  61 in total

1.  Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro.

Authors:  A Gillissen; M Jaworska; M Orth; M Coffiner; P Maes; E M App; A M Cantin; G Schultze-Werninghaus
Journal:  Respir Med       Date:  1997-03       Impact factor: 3.415

2.  Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures.

Authors:  Gail D Zeevalk; Laura P Bernard
Journal:  Antioxid Redox Signal       Date:  2005 May-Jun       Impact factor: 8.401

3.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

4.  Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are associated with mitochondrial dysfunction.

Authors:  Lisa M Domico; Gail D Zeevalk; Laura P Bernard; Keith R Cooper
Journal:  Neurotoxicology       Date:  2006-07-22       Impact factor: 4.294

Review 5.  Recent advances in liposomal drug-delivery systems.

Authors:  A Chonn; P R Cullis
Journal:  Curr Opin Biotechnol       Date:  1995-12       Impact factor: 9.740

6.  Potentiation of excitotoxic injury by high concentrations of extracellular reduced glutathione.

Authors:  R F Regan; Y P Guo
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 7.  Metabolism and functions of glutathione in brain.

Authors:  R Dringen
Journal:  Prog Neurobiol       Date:  2000-12       Impact factor: 11.685

8.  Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.

Authors:  Robert A Hauser; Kelly E Lyons; Terry McClain; Summer Carter; David Perlmutter
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

9.  Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate).

Authors:  G Meco; V Bonifati; N Vanacore; E Fabrizio
Journal:  Scand J Work Environ Health       Date:  1994-08       Impact factor: 5.024

10.  Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat.

Authors:  R Kannan; J F Kuhlenkamp; E Jeandidier; H Trinh; M Ookhtens; N Kaplowitz
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

View more
  16 in total

1.  Commentary to "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione".

Authors:  Frederick T Guilford
Journal:  Eur J Nutr       Date:  2015-08       Impact factor: 5.614

2.  Liposomes as Advanced Delivery Systems for Nutraceuticals.

Authors:  Christopher W Shade
Journal:  Integr Med (Encinitas)       Date:  2016-03

Review 3.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

Review 4.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

Review 5.  Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems.

Authors:  Ivana Cacciatore; Leonardo Baldassarre; Erika Fornasari; Adriano Mollica; Francesco Pinnen
Journal:  Oxid Med Cell Longev       Date:  2012-06-03       Impact factor: 6.543

6.  Liposomal Antioxidants for Protection against Oxidant-Induced Damage.

Authors:  Zacharias E Suntres
Journal:  J Toxicol       Date:  2011-08-16

7.  Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Authors:  Carlos Spuch; Carmen Navarro
Journal:  J Drug Deliv       Date:  2011-12-13

Review 8.  A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins.

Authors:  Janette Hope
Journal:  ScientificWorldJournal       Date:  2013-04-18

Review 9.  Chelation: harnessing and enhancing heavy metal detoxification--a review.

Authors:  Margaret E Sears
Journal:  ScientificWorldJournal       Date:  2013-04-18

10.  S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease.

Authors:  Carmen R Sunico; Tomohiro Nakamura; Edward Rockenstein; Michael Mante; Anthony Adame; Shing Fai Chan; Traci Fang Newmeyer; Eliezer Masliah; Nobuki Nakanishi; Stuart A Lipton
Journal:  Mol Neurodegener       Date:  2013-08-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.